% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{AlMonajjed:301763,
author = {R. Al-Monajjed$^*$ and M. Boschheidgen and J. Lakes and A.
Krilaviciute$^*$ and J.-P. Radtke and H.-P. Schlemmer$^*$
and D. Bonekamp$^*$ and K. Herkommer and M. Jahnen and J. E.
Gschwend and D. Düx and F. Wacker and M. R. Makowski and A.
Sauter and M. A. Kuczyk and N. Harke and J. Debus and C.
Grott and C. Arsov and P. Seibold$^*$ and B. Hadaschik$^*$
and F. Giesel and G. Kristiansen and G. Antoch and N.
Becker$^*$ and R. Kaaks$^*$ and L. Schimmöller and P.
Albers$^*$},
title = {{P}rostate {C}ancer {D}etection in {Y}ounger {M}en: {A}
{C}omparative {A}nalysis of {S}ystematic and {M}agnetic
{R}esonance {I}maging-targeted {B}iopsy in the {PROBASE}
{T}rial.},
journal = {European urology},
volume = {88},
number = {3},
issn = {0302-2838},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2025-01143},
pages = {240-244},
year = {2025},
note = {#EA:C130#LA:C130# / 2025 Sep;88(3):240-244},
abstract = {The optimal approach for prostate cancer (PC) screening,
including the ideal starting age and most effective
diagnostic method, remains under investigation. We evaluated
the diagnostic performance of magnetic resonance imaging
(MRI)-targeted biopsy (TBx) and systematic biopsy (SBx) in
detecting clinically significant PC (csPC) in men aged 45-50
yr in PROBASE, a prospective, randomized trial of a
risk-adapted screening strategy. A total of 525 participants
with elevated prostate-specific antigen (≥3 ng/ml)
underwent MRI followed by biopsy. Of the 209 PC cases
detected, 148 $(71\%)$ were csPC. SBx identified $94\%$ of
csPC cases, while TBx detected $74\%$ (p ≤ 0.05). SBx also
diagnosed significantly more low-grade PCs than TBx (p <
0.001). These findings suggest that relying solely on
MRI-TBx may lead to underdiagnosis of csPC. Combining SBx
with TBx remains the most effective strategy for early
detection of PC in young men undergoing screening. Future
research should explore optimization strategies to reduce
unnecessary biopsies while maintaining high detection rates
for csPC. This trial is registered on the ISRCTN registry as
ISRCTN37591328 (https://www.isrctn.com/ISRCTN37591328). The
study protocol can be accessed at
https://doi.org/10.1016/j.eururo.2013.05.022.},
keywords = {Fusion biopsy (Other) / Magnetic resonance imaging (Other)
/ Prostate cancer (Other) / Prostate-specific antigen
(Other) / Risk-adapted screening (Other) / Ultrasound
(Other)},
cin = {C130 / E010 / ED01 / C020},
ddc = {610},
cid = {I:(DE-He78)C130-20160331 / I:(DE-He78)E010-20160331 /
I:(DE-He78)ED01-20160331 / I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40461322},
doi = {10.1016/j.eururo.2025.05.020},
url = {https://inrepo02.dkfz.de/record/301763},
}